share_log

JP Morgan Maintains Overweight on ResMed, Raises Price Target to $195

Benzinga ·  Jan 9 09:33

JP Morgan analyst David Low maintains ResMed (NYSE:RMD) with a Overweight and raises the price target from $160 to $195.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment